Chromocell Therapeutics Corporation (CHRO)
- Previous Close
2.0100 - Open
2.0166 - Bid 1.6100 x 1100
- Ask 2.4000 x 800
- Day's Range
1.6400 - 2.1200 - 52 Week Range
1.2100 - 6.0000 - Volume
49,078 - Avg. Volume
25,063 - Market Cap (intraday)
10.286M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
www.chromocell.comRecent News: CHRO
Performance Overview: CHRO
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHRO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHRO
Valuation Measures
Market Cap
10.29M
Enterprise Value
11.46M
Trailing P/E
121.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.58
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-241.46%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.98M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
3.77M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.19M
Research Analysis: CHRO
Company Insights: CHRO
CHRO does not have Company Insights